Information Provided By: 
Fly News Breaks for September 3, 2015
CMRX
Sep 3, 2015 | 06:34 EDT
Citi analyst Yigal Nochomovitz started shares of Chimerix with a Buy rating and $80 price target. The analyst has "high conviction" that the company's brincidofovir will "transform" the lives of transplant patients and the standard of care in multiple transplant settings. Nochomovitz also calls a takeout thesis "not outrageous." Chimerix is the analyst's top pick in the small- and mid-cap biotech space.
News For CMRX From the Last 2 Days
There are no results for your query CMRX
